AbbVie has submitted an application to the FDA for the approval of TrenibotE — the first-in-class botulinum toxin type E. The product demonstrates a record-fast onset of action (8 hours) and a short duration of effect (2-3 weeks), which may change the approach to initial injections in patients who have previously avoided neurotoxins.

Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxin A) for the Treatment of Moderate to Severe Glabellar Lines.